The lowest price of more than 3 billion varieties is refreshed.

Recently, Shaanxi Province Public Resources Trading Center issued "newly approved drug-related information", Cinda Bio's Beval zhu sing-net price was announced, the price of 1188 yuan / bottle (4ml: 100mg)June 19 this year, Cinda Bio's Bevalzhu zuma biosimilar drug obtained the drug approval certificate, officially obtained the State Drug Administration approved the listing, this is China's second domestic beivalzumab biosimilar drugData show that beva-beadssss is an anti-tumor angiogenesis inhibitor, can block the growth of tumor new blood vessels, and tumor cell growth and metastasis and the generation of new blood vessels are greatly related, the new blood vessels is the way of tumor nutrition supply, bevele supreminate can block the binding between receptors to inhibit tumor angiogenesisOn December 9, 2019, The bevalo-beaded monoto-injection liquid (commodity name: Amada) developed by Qilu Pharmaceutical Co., Ltdwas approved for listing, which is the first approved biosimilar drug of Beva zhusiton in ChinaData show that Roche's Bevalzumab was approved by the CFDA in 2010 for the market, the dosage form is 100mg (4ml) and 400mg (16ml)Cyberblue in the Minnet database query found that the sales of the 2019 national public hospital terminal sales of the BevalZumab, 2015-2019 has maintained an upward trendDecember 2019, Qilu Pharmaceuticals' domestic betovastatin-on-the-net quickly grabbed 0.26 percent of the market share from Rochethis year, with Cinda Bio's hanging network and Qilu Pharmaceuticals to further promote the release, domestic similar drugs may eat into Roche's original research more marketsRoche's 2019 financial results reported full-year revenue of CHF 61.5 billion, up 8% year-on-year, with revenues from the pharmaceutical sector of SFr48.5 billion (?10%) and diagnostics revenueof SFr12.9 billion (-1%)In terms of specific products, the anti-tumor "three swordsman" Bevalzumab was 7,073 million Swiss francs (52.9 billion yuan), up 4% YoY, while qutodbead monoidat (60.39 million, -12%) and litoxisiamin (6.477 billion, -4%) remained basically stableRoche's earnings performance was "mixed" - breaking Pfizer's four-year dominance to number one in the US's annual list of the world's top 50 pharmaceutical companiesIt is understood that bevalo-bead monotonica is still Roche's best-selling products, accounting for 15% of the company's total drug revenue, but as quralson and rituximatodhasa have experienced, in the next few years, bevalo zumas also face competition from biologically similar drugsOver 1.5 billion varieties, again reduced prices of the original research drug Bevalpzumab (Anvitin) (100mg:4ml) list price of 5398 yuan, its price on July 19, 2017 after entering health insurance fell to 1998 yuan (100mg:4ml/bottle)The price will be cut again after the 2019 health insurance renewal, although the price has not been announced, but the timing of the renewal talks coincides with the launch of Qilu's first biosimilar, a new round of price cuts is inevitableAccording to the bidding information of Minnet.com, on January 9th Anvetin (4ml:100mg) won the bid price in Fujian at RMB1934.26, which is for reference onlyOn December 17, 2019, Qilu Pharmaceuticals declared the Bevalbead sing-only injection (spec: 4ml: 0.1g) was officially sold at 1266 yuan/branch, which was 1934.26 yuan/4ml:100mg, a decrease of 34.55% After that, Qilu in many provinces are 1198 yuan / bottle / 100mg: 4ml price net, the price became the next listing of pharmaceutical companies pricing ceiling This time, Cinda Bio to 1188 yuan / bottle (4ml: 100mg) price hanging net, and then create the lowest market price of this variety Drug data show that in the domestic research and development competition of beifa-beads monoantithetic drugs, the number of declared enterprises has reached more than 20, in addition to Qilu Pharmaceuticals and Cinda Bio, in April 2020, Hengrui Pharmaceuticals' beverazzumab biosimilar drug listing application was accepted by CDE; In addition to the head enterprises, the variety also has Fuhong Hanxuan, Shandong Bo'an biological technology, Dongyi Pharmaceuticals, Tianguang real biology, Bai Otai biology, Anhui Anke and other more than 10 enterprises are being declared In recent years, domestic pharmaceutical companies continue to upgrade from generic to innovative drugs to explore, but still due to the rapid changes in the policy environment, lack of research and development capacity and other reasons, even in the field of innovative drugs there is a "high level of repeated construction" situation The heavy-duty biosimilar drug headed by Beval-Zuma is a typical case - because the rapid overseas release speed and higher sales amount attracted the attention of many domestic research and development enterprises, coupled with biosimilars more in line with domestic enterprises from imitation to innovative ideas, resulting in domestic pharmaceutical companies in such heavy biological similar drugs in the competition for research and development is extremely fierce At present, the competition pattern of the first echelon of Beval-Zhu sing-against has been relatively clear, follow-up successful listing of enterprises, product pricing has been lower than previously expected, now Cinda Bio's product pricing as low as 1188 yuan / bottle (4ml: 100mg), follow-up products taking into account research and development costs, production costs, circulation costs, national taxes and corporate profits and other conditions, combined with fierce market competition, pricing or will fall below a thousand yuan